solo per uso di ricerca

Triptolide Hsp90 Middle Domain Inhibitor

N. Cat.: S3604

Triptolide è un triepossido diterpenico, un agente immunosoppressivo estratto dall'erba cinese Tripterygium wilfordii. Funziona come inibitore di NF-κB con duplice azione, interrompendo l'interazione p65/CBP e riducendo la proteina p65. Triptolide (PG490) abroga la funzione di transattivazione del fattore di trascrizione da shock termico 1 (HSF1). Triptolide inibisce MDM2 e induce l'apoptosi attraverso una via indipendente da p53.
Triptolide ADC Cytotoxin Chimico Chemical Structure

Struttura chimica

Peso molecolare: 360.4

Vai a

Controllo Qualità (Quality Control)

Lotto: Purezza: 99.95%
99.95

Coltura cellulare, trattamento e concentrazione di lavoro
(Cell Culture, Treatment & Working Concentration)

Linee cellulari Tipo di saggio Concentrazione Tempo di incubazione Formulazione Descrizione dell'attività PMID
HT-29 Cytotoxicity against Cytotoxicity against human HT-29 cells, IC50=0.0021μM 21470864
HCT116 Cytotoxicity against Cytotoxicity against human HCT116 cells assessed as decrease in cell viability, IC50=0.0047μM 31121546
SKOV3 Antiproliferative activity against 72 hrs Antiproliferative activity against human SKOV3 cells after 72 hrs by SRB assay, IC50=0.006μM 20833543
SKOV3 Cytotoxicity against 72 hrs Cytotoxicity against human SKOV3 cells after 72 hrs by sulforhodamine B assay, IC50=0.006μM 24378709
SKOV3 Cytotoxic activity against 72 hrs Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0072μM 28011223
KBM5 Cytotoxicity against 72 hrs Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay, IC50=0.0083μM 20149665
SKOV3 Cytotoxicity against Cytotoxicity against human SKOV3 cells by SRB assay, IC50=0.009μM 19637874
MDA-MB-468 Cytotoxicity against Cytotoxicity against human MDA-MB-468 cells by SRB assay, IC50=0.01μM 19637874
HCT116 Cytotoxicity against 72 hrs Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay, IC50=0.01μM 19637874
SKOV3 Cytotoxicity against 72 hrs Cytotoxicity against human SKOV3 cells after 72 hrs by MTT assay, IC50=0.01μM 19637874
KBM5 Cytotoxicity against 72 hrs Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl after 72 hrs by MTS assay, IC50=0.0103μM 20149665
Rh30 Cytotoxicity against 72 hrs Cytotoxicity against human Rh30 cells after 72 hrs by MTT assay, IC50=0.014μM 19637874
A549 Antagonist activity at Antagonist activity at human PAR2 expressed in human A549 cells assessed as inhibition of 2f-LIGRLO-NH2-induced NFkappaB activation by luciferase reporter gene assay, IC50=0.014μM 23895492
SGC7901 Cytotoxicity against 72 hrs Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay, IC50=0.015μM 19637874
MOLT4 Cytotoxicity against 72 hrs Cytotoxicity against human MOLT4 cells after 72 hrs by MTT assay, IC50=0.017μM 19637874
A549 Cytotoxic activity against 72 hrs Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0175μM 28011223
SMMC7721 Cytotoxicity against 72 hrs Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay, IC50=0.018μM 19637874
PC3 Cytotoxic activity against 72 hrs Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay, IC50=0.0183μM 28011223
MCF7 Cytotoxicity against 72 hrs Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay, IC50=0.019μM 19637874
A549 Cytotoxicity against Cytotoxicity against human A549 cells, IC50=0.019μM 21470864
PC3 Cytotoxicity against Cytotoxicity against human PC3 cells by SRB assay, IC50=0.02μM 19637874
Bel7402 Cytotoxicity against 72 hrs Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay, IC50=0.02μM 19637874
PC3 Antiproliferative activity against 72 hrs Antiproliferative activity against human PC3 cells after 72 hrs by SRB assay, IC50=0.02μM 20833543
PC3 Cytotoxicity against 72 hrs Cytotoxicity against human PC3 cells after 72 hrs by sulforhodamine B assay, IC50=0.02μM 24378709
PC3 Cytotoxicity against Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation by sulforhodamine B assay, IC50=0.02μM 25467158
786-O Cytotoxicity against 72 hrs Cytotoxicity against human 786-O cells after 72 hrs by MTT assay, IC50=0.022μM 19637874
A549 Antagonist activity at Antagonist activity at human PAR2 expressed in human A549 cells coexpressing TACR1 assessed as inhibition of substance P-induced IL-8 production by ELISA, IC50=0.023μM 23895492
MDA-MB-231 Cytotoxicity against 72 hrs Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay, IC50=0.024μM 19637874
DU145 Cytotoxicity against 72 hrs Cytotoxicity against human DU145 cells after 72 hrs by MTT assay, IC50=0.024μM 19637874
HO8910 Cytotoxicity against 72 hrs Cytotoxicity against human HO8910 cells after 72 hrs by MTT assay, IC50=0.028μM 19637874
HCT15 Cytotoxicity against 72 hrs Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay, IC50=0.029μM 19637874
A549 Growth inhibition of human Growth inhibition of human A549 cells, IC50=0.03μM 28814374
32D Cytotoxicity against 72 hrs Cytotoxicity against mouse 32D cells harboring wild type Bcr-Abl after 72 hrs by MTS assay, IC50=0.032μM 20149665
U251 Cytotoxicity against Cytotoxicity against human U251 cells assessed as inhibition of cell proliferation by sulforhodamine B assay, IC50=0.033μM 25467158
32D Cytotoxicity against 72 hrs Cytotoxicity against imatinib-resistant mouse 32D cells harboring Bcr-Abl T315I mutant after 72 hrs by MTS assay, IC50=0.034μM 20149665
PC3 Cytotoxicity against 72 hrs Cytotoxicity against human PC3 cells after 72 hrs by MTT assay, IC50=0.043μM 19637874
KB Cytotoxicity against 72 hrs Cytotoxicity against human KB cells after 72 hrs by MTT assay, IC50=0.043μM 19637874
HepG2 Cytotoxicity against 48 hrs Cytotoxicity against human HepG2 cells after 48 hrs by XTT assay, IC50=0.0433μM 30613335
HeLa Cytotoxicity against 72 hrs Cytotoxicity against human HeLa cells after 72 hrs by MTT assay, IC50=0.047μM 19637874
U251 Cytotoxicity against 72 hrs Cytotoxicity against human U251 cells after 72 hrs by MTT assay, IC50=0.049μM 19637874
K562 Cytotoxicity against 72 hrs Cytotoxicity against human K562 cells after 72 hrs by MTT assay, IC50=0.05μM 19637874
NIH/3T3 Cytotoxicity against Cytotoxicity against mouse NIH/3T3 cells assessed as decrease in cell viability, IC50=0.05μM 31121546
SW1116 Cytotoxicity against 72 hrs Cytotoxicity against human SW1116 cells after 72 hrs by MTT assay, IC50=0.052μM 19637874
A549 Cytotoxicity against 72 hrs Cytotoxicity against human A549 cells after 72 hrs by MTT assay, IC50=0.059μM 19637874
HeLa Cytotoxicity against Cytotoxicity against human HeLa cells assessed as decrease in cell viability, IC50=0.087μM 31121546
Jurkat Cytotoxicity against Cytotoxicity against human Jurkat cells assessed as decrease in cell viability, IC50=0.14μM 31121546
MKN28 Cytotoxicity against 72 hrs Cytotoxicity against human MKN28 cells after 72 hrs by MTT assay, IC50=0.2μM 19637874
MDCK Cytotoxicity against Cytotoxicity against MDCK cells assessed as decrease in cell viability, IC50=1.2μM 31121546
Pkd1-/- Induction of Induction of cell growth arrest in mouse Pkd1-/- cells in presence of calcium 17360534
Pkd1-/- Increase in 100 nM 96 hrs Increase in p21CIP/WAF expression in mouse Pkd1-/- cells at 100 nM after 96 hrs by Western blot analysis 17360534
Pkd1+/- Increase in 100 nM Increase in PC2 dependent calcium release in mouse Pkd1+/- cells at 100 nM 17360534
Pkd1-/- Increase in 100 nM Increase in PC2 dependent calcium release in mouse Pkd1-/- cells at 100 nM 17360534
Pkd1-/- Increase in 50 uM Increase in calcium release in mouse Pkd1-/- cells at 50 uM in presence of RyR antagonist dantrolene 17360534
Pkd2+/- Growth inhibition of PC2 expressing mouse 100 nM 24 hrs Growth inhibition of PC2 expressing mouse Pkd2+/- cells as cell death at 100 nM after 24 hrs 17360534
KBM5 Cytotoxicity against 0.001 to 17 uM 72 hrs Cytotoxicity against human KBM5 cells harboring wild type Bcr-Abl at 0.001 to 17 uM after 72 hrs by MTS assay 20149665
KBM5 Cytotoxicity against 0.001 to 17 uM 72 hrs Cytotoxicity against imatinib-resistant human KBM5 cells harboring Bcr-Abl T315I mutant at 0.001 to 17 uM after 72 hrs by MTS assay 20149665
LNCAP Antagonist activity at 5 uM 24 hrs Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 5 uM after 24 hrs by dual luciferase reporter gene assay 27994731
LNCAP Antagonist activity at 500 nM 24 hrs Antagonist activity at AR in human LNCAP cells assessed as suppression of DHT-induced receptor transcriptional activity at 500 nM after 24 hrs by dual luciferase reporter gene assay 27994731
HepG2 Antitumor activity against 0.2 mg/kg 15 days Antitumor activity against human HepG2 cells xenografted in Balb/c nude mouse assessed as reduction in tumor growth at 0.2 mg/kg, ip administered once daily for 15 days 30613335
Clicca per visualizzare più dati sperimentali sulle linee cellulari

Informazioni chimiche, conservazione e stabilità (Chemical Information, Storage & Stability)

Peso molecolare 360.4 Formula

C20H24O6

Conservazione (Dalla data di ricezione)
N. CAS 38748-32-2 Scarica SDF Conservazione delle soluzioni stock

Solubilità (Solubility)

In vitro
Lotto:

DMSO : 72 mg/mL (199.77 mM)
(Il DMSO contaminato da umidità può ridurre la solubilità. Utilizzare DMSO fresco e anidro.)

Water : Insoluble

Ethanol : Insoluble

Calcolatore di Molarità

Massa Concentrazione Volume Peso molecolare
Calcolatore di Diluizione Calcolatore del Peso Molecolare

In vivo
Lotto:

Calcolatore di formulazione in vivo (Soluzione chiara)

Passo 1: Inserire le informazioni di seguito (Consigliato: Un animale aggiuntivo per tenere conto della perdita durante l'esperimento)

mg/kg g μL

Passo 2: Inserire la formulazione in vivo (Questo è solo il calcolatore, non la formulazione. Contattateci prima se non c'è una formulazione in vivo nella sezione Solubilità.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Risultati del calcolo:

Concentrazione di lavoro: mg/ml;

Metodo per preparare il liquido master di DMSO: mg farmaco predissolto in μL DMSO ( Concentrazione del liquido master mg/mL, Vi preghiamo di contattarci prima se la concentrazione supera la solubilità del DMSO del lotto del farmaco. )

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungereμL PEG300, mescolare e chiarire, quindi aggiungereμL Tween 80, mescolare e chiarire, quindi aggiungere μL ddH2O, mescolare e chiarire.

Metodo per preparare la formulazione in vivo: Prendere μL DMSO liquido master, quindi aggiungere μL Olio di mais, mescolare e chiarire.

Nota: 1. Si prega di assicurarsi che il liquido sia limpido prima di aggiungere il solvente successivo.
2. Assicurarsi di aggiungere il/i solvente/i in ordine. È necessario assicurarsi che la soluzione ottenuta, nell'aggiunta precedente, sia una soluzione limpida prima di procedere all'aggiunta del solvente successivo. Metodi fisici come il vortex, gli ultrasuoni o il bagno d'acqua calda possono essere utilizzati per facilitare la dissoluzione.

Meccanismo d'azione (Mechanism of Action)

Targets/IC50/Ki
NF-κB
HSF1
MDM2
In vitro
Triptolide is a diterpene triepoxide with potent immunosuppressive and antiinflammatory properties. This compound is shown to inhibit the expression of IL-2 in activated T cells at the level of purine-box/nuclear factor and NF-κB mediated transcription activation. It inhibits the proliferation and colony formation of tumor cells at extremely low concentrations (2–10 ng/mL). This chemical has an inhibitory activity on breast, stomach and leukemia cell line HL-60 cells. It induces apoptosis in tumor cells by blocking NF-κB activation and sensitizing tumor cells for TNF-&alpha induced programmed cell death.
In vivo
Triptolide synergizes with cyclosporin A in promoting graft survival in animal models and in suppression of graft versus host disease in allogeneic bone marrow transplants. In addition, it induces apoptosis in tumor cells and potentiates tumor necrosis factor (TNF-α) induction of apoptosis in part through the suppression of c-IAP2 and c-IAP1 induction. This compound treatment for 2–3 weeks inhibits the growth of xenografts formed by four different tumor cell lines (B16 melanoma, MDA-435 breast cancer, TSU bladder cancer, and MGC80-3 gastric carcinoma), indicating that TPL has a broad spectrum of activity against tumors that contain both wild-type and mutant forms of p53. In addition, it inhibits experimental metastasis of B16F10 cells to the lungs and spleens of mice. It has in vitro and in vivo activities against mouse models of polycystic kidney disease. LD50: Mice 0.83mg/kg (i.v.).
Riferimenti
  • [4] https://pubmed.ncbi.nlm.nih.gov/17360534/
  • [5] https://pubmed.ncbi.nlm.nih.gov/23583804/

Applicazioni (Applications)

Metodi Biomarcatori Immagini PMID
Western blot c-Jun MDM2 p-AKT / AKT / p-Foxo3a / Foxo3a / p53 p-PI3K / PI3K / p85 / p110
S3604-WB1
22666381
Growth inhibition assay Cell viability
S3604-viability1
22666381

Informazioni sullo studio clinico (Clinical Trial Information)

(dati da https://clinicaltrials.gov, aggiornato il 2026-03-05)

Numero NCT Reclutamento Condizioni Sponsor/Collaboratori Data di inizio Fasi
NCT05166616 ACTIVE_NOT_RECRUITING
Advanced Lung Non-Small Cell Carcinoma; Locally Advanced Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8; Unresectable Lung Non-Small Cell Carcinoma
City of Hope Medical Center
2022-03-07 PHASE1
NCT03403569 COMPLETED
HIV-infection/AIDS
Peking Union Medical College Hospital
2018-09-01 PHASE3
NCT02219672 UNKNOWN
AIDS/HIV PROBLEM
Peking Union Medical College
2014-07 PHASE3
NCT02115659 UNKNOWN
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Shanghai Changzheng Hospital
2014-04 PHASE3
NCT01817283 UNKNOWN
HIV
LI Taisheng
2013-01 PHASE1; PHASE2
NCT00801268 TERMINATED
Polycystic Kidney
Zhi-Hong Liu, M.D.
2008-11